Payment overview · 2025
General Payments
$94.46
2 reported records · 2 companies
Healthcare provider profile · identity verified
Vidal A Febles
Allopathic & Osteopathic Physicians|Family Medicine · PENUELAS, PR · NPI 1578528634
Verified facts
What the public records show
CMS Open Payments records show Vidal A Febles received $94.46 in general payments during 2025 across 2 reported records.
GlaxoSmithKline, LLC. accounted for 54.3% of that reported general-payment amount.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $51.30 | 54.3% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $43.16 | 45.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $94.46 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
Payment records were found, but the reported records did not identify a specific associated product for this analysis.
Public prescribing for products named in payments
There is no explicit payment-product set available for a Part D comparison.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Simvastatin | Simvastatin | 889 | 169 |
| Famotidine | Famotidine | 622 | 133 |
| Atorvastatin Calcium | Atorvastatin Calcium | 590 | 134 |
| Gabapentin | Gabapentin | 568 | 124 |
| Losartan Potassium | Losartan Potassium | 560 | 108 |
| Metformin Hcl | Metformin Hcl | 453 | 94 |
| Synthroid | Levothyroxine Sodium | 429 | 67 |
| Lisinopril | Lisinopril | 420 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 388 | 94 |
| Metoprolol Succinate | Metoprolol Succinate | 369 | 77 |
| Levothyroxine Sodium | Levothyroxine Sodium | 342 | 75 |
| Omeprazole | Omeprazole | 341 | 72 |
| Pantoprazole Sodium | Pantoprazole Sodium | 317 | 60 |
| Glipizide Er | Glipizide | 247 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 231 | 51 |
| Farxiga | Dapagliflozin Propanediol | 225 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 209 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 38 |
| Glimepiride | Glimepiride | 179 | 34 |
| Glipizide | Glipizide | 162 | 34 |
| Enalapril Maleate | Enalapril Maleate | 159 | 29 |
| Carvedilol | Carvedilol | 143 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 25 |
| Allopurinol | Allopurinol | 127 | 20 |
| Furosemide | Furosemide | 126 | 35 |
| Irbesartan | Irbesartan | 125 | 24 |
| Meclizine Hcl | Meclizine Hcl | 121 | 40 |
| Ezetimibe | Ezetimibe | 117 | 28 |
| Alendronate Sodium | Alendronate Sodium | 112 | 29 |
| Fenofibrate | Fenofibrate | 110 | 27 |
| Nabumetone | Nabumetone | 110 | 57 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 103 | 21 |
| Clonazepam | Clonazepam | 97 | 26 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 94 | 52 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 94 | 14 |
| Finasteride | Finasteride | 91 | 22 |
| Sertraline Hcl | Sertraline Hcl | 85 | 14 |
| Atenolol | Atenolol | 81 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 78 | 16 |
| Montelukast Sodium | Montelukast Sodium | 77 | 21 |
| Eliquis | Apixaban | 74 | 17 |
| Chlorthalidone | Chlorthalidone | 70 | 11 |
| Lansoprazole | Lansoprazole | 69 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 66 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 61 | 16 |
| Sulindac | Sulindac | 61 | 18 |
| Humalog | Insulin Lispro | 60 | suppressed |
| Jardiance | Empagliflozin | 59 | 11 |
| Donepezil Hcl | Donepezil Hcl | 58 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 15 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 52 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 52 | 17 |
| Warfarin Sodium | Warfarin Sodium | 51 | suppressed |
| Januvia | Sitagliptin Phosphate | 48 | 11 |
| Temazepam | Temazepam | 48 | 14 |
| Cilostazol | Cilostazol | 46 | suppressed |
| Latanoprost | Latanoprost | 45 | 11 |
| Tradjenta | Linagliptin | 45 | suppressed |
| Nifedipine Er | Nifedipine | 43 | suppressed |
| Xarelto | Rivaroxaban | 43 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 42 | 12 |
| Baclofen | Baclofen | 41 | 21 |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 38 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Spironolactone | Spironolactone | 38 | suppressed |
| Pentoxifylline | Pentoxifylline | 37 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 33 | 17 |
| Naproxen | Naproxen | 33 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 32 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Humulin N | Insulin Nph Human Isophane | 30 | suppressed |
| Verapamil Er | Verapamil Hcl | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | 15 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Colchicine | Colchicine | 27 | suppressed |
| Brilinta | Ticagrelor | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 26 | 12 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 26 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 22 |
| Alprazolam | Alprazolam | 25 | suppressed |
| Azithromycin | Azithromycin | 25 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 25 | suppressed |
| Memantine Hcl | Memantine Hcl | 25 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 24 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 24 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 23 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Meloxicam | Meloxicam | 22 | 11 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 22 | suppressed |
| Advocate Syringes | Syring-Needl,disp,insul,0.3 Ml | 21 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 21 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 21 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 21 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 21 | suppressed |
| Advocate Syringes | Syringe-Needle,insulin,0.5 Ml | 20 | suppressed |
| Indapamide | Indapamide | 20 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 19 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Advocate Syringes | Syringe And Needle,insulin,1ml | 17 | suppressed |
| Etodolac | Etodolac | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 16 | suppressed |
| Ramipril | Ramipril | 16 | suppressed |
| Sure Comfort | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 15 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 14 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 12 | suppressed |
| Insulin Glargine | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Levoxyl | Levothyroxine Sodium | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Timolol Maleate | Timolol Maleate | 12 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 11 | suppressed |
| Captopril | Captopril | 11 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 11 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 11 | suppressed |
| Pen Needles | Pen Needle, Diabetic | 11 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 11 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $94.46 · 2 records | GlaxoSmithKline, LLC. | — | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error